S.L. 31.18 Art. 17Saving. 8, 9, 10- [b, d) acid PARAHEXYL PCE, PHP, PCPY, PMA PSILOCINE, PSILOCYBINE STP. DOM following chemical TCP, TMA mCPP oCPP pCPP 2C-1 2C-T-2 2C-T-7 TMA-2 PMMA 4-MTA 5-IT 25I-NBOMe 25B-NBOMe 25C-NBOMe Methylone JWH-018 acetate; 6,6,9- H4-CBD, CBD, THD, THC-P, THCP HHCH, Delta-8-THCP, heptyl THC

Any dispensed prescription, register, record, invoice or other document which, immediately before the coming into force of these Regulations, are preserved under the Drugs (Control) * Regulations, 1976, shall continue to be preserved and to be open for inspection and shall for these purposes be deemed to have always been preserved under these regulations.

*Revoked by these Regulations.  FIRST SCHEDULE Substituted by:  L.N. 70 of 1988.  Amended by:  L.N. 183 of 1999;  L.N. 173 of 2010;  L.N. 424 of 2010;  L.N. 148 of 2012;  L.N. 363 of 2013;  L.N. 365 of 2013;  L.N. 405 of 2013;  L.N. 47 of 2016;  L.N. 355 of 2017;  L.N.361 of 2017;  L.N. 229 of 2018;  L.N. 267 of 2018;  L.N. 191 of 2019;  L.N. 112 of 2021;  L.N. 238 of 2024; L.N. 99 of 2025.

(Regulation 2)

International or other nonproprietary name Chemical name or other trivial name α-PVP 1-phenyl-2-(1-pyrrolidin-1-yl)pentan-1-one CATHINONE (-)-a-aminopropiophenone DET N.N-diethyltryptamine DMA d1-2,5-dimethoxy-a-methylphenylethylamine DMHP 3-(1,2-dimethylheptyl)-l-hydroxy-7, tetrahydro-6, 6, 9-trimethyl-6Hdibenzo pyran DMT N.N-dimethyltryptamine DOB, BROLAMFETAMINE 2,5-dimethoxy-4-bromoamphetamine (+) LYSERGIDE, LSD, LSD-25 (+)-N.N-diethyllysergamide (d-lysergic diethylamide) DOET dl-2, 5-dimethoxy-4-ethyl-a methylphenylethylamine ENTRYPTAMINE 3-(2-aminobutyl) indole  MDA, METHYLENE 3,4, methylenedioxyamphetamine DIOXYAMPHETAMINE MDMA, TENAMFETAMINE dl-3, 4-methylenedioxy-N, a-dimethylphenylethylamine 4,4’-DMAR 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine 4-MA 4-methylamphetamine mephedrone (4-methylmethcathinone) 2-methylamino-1-(4-methylphenyl)propan-1-one METHCATHINONE 2-(methylamino)-1-phenylpropan-1-one Methoxetamine 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone MESCALINE, MESCAL  3, 4, 5-trimethoxyphenethylamine BUTTON, PEYOTE, PEYOTL MMDA 2-methoxy-alpha-methyl-4-5-(methylenedioxy)phenethylamine 3-hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d) pyran ETICYCLIDINE N-ethyl-l-phenylcyclohexylamine ROLICYCLIDINE 1-(1-phenylcyclohexyl) pyrrolidine 4-methoxy-a-methylphenylethylamine PSILOTSIN 3-(2-dimethylaminoethyl)-4-hydroxyindole 3-(2-dimethylaminoethyl)-indol-4-y1 dihydrogen phosphate 2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane TETRAHYDROCANNABINOL, 7, 8, 9, 10 - tetrahydro-6,6,9-trimethyl-isomers and their stereo thepentyl- 6H-dibenzo[b,d]pyran-1-ol variants (9R,10aR)-8,9,10,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-6H-ibenzo[b,d]pyran-1-ol (6aR,9R,10aR)- 6a,9,10,10a-tetrahydro-6, 6,9-trimethyl-3pentyl-6H-ibenzo[b,d]pyran-1-ol (6aR,10aR)- 6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3pentyl-6H-dibenzo[b,d]pyran-1-ol 6a,7,8,9-tetrahydro-6, 6,9-trimethyl-3pentyl-6H-dibenzo[b,d]pyran-1-ol (6aR,10aR)- 6a,7,8,9,10,10a-hexahydro-6, 6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran-1-ol TENOCYCLIDNE 1-[1-(2-thienyl) cyclohexyl) piperidine dl-3, 4, 5-trimethoxy-a-methylphenylethylamine 1-(3-chlorophenyl)piperazine 1-(2-chlorophenyl)piperazine 1-(4-chlorophenyl)piperazine 1-BENZYLPIPERAZINE 1-benzyl-1, 4-diazacyclohexane (2,5-dimethoxy-4-iodophenethylamine) (2,5-dimethoxy-4-ethylthiophenethylamine) (2,5-dimethoxy-4-(n)-propylthiophenethylamine) (2,4,5,-trimethoxyamphetamine) paramethoxymethylamphetamine or N-methyl-1-(4-methoxy-phenyl)-2-aminopropane ( -methyl-4-methylthiophenethylamine) 5-(2-aminopropyl)indole (2C-I-NBOMe) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-B-NBOMe) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 3,4-methylenedioxypyrovalerone (MDPV) (RS)-1-(Benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (beta-keto-MDMA) (±)-2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one Naphthalen-1-yl-(1-pentylindol-3-yl)methanone AM-2201 1-[(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalene-1-yl)methanone 2-(ethylamino)-1-(4-methylphenyl)propan-1-4-MEC (4-methylethcathinone) one 1-(2H-1,3-benzodioxol-5-yl)-2-Ethylone (ethylamino)propan-1-one 2-(methylamino)-1-phenylpentan-1-one Pentedrone (α-methylaminovalerophenone) Ethylphenidate (EPH) ethyl phenyl(piperidin-2-yl)acetate Methiopropamine (MPA) N-methyl-1-(thiophen-2-yl)propan-2-amine methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-MDMB-CHMICA yl]carbonyl}-3-methyl-L-valinate N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-5F-APINACA (5F-AKB-48) indazole-3-carboxamide [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-XLR-11 tetramethylcyclopropyl)methanone". AB-CHMINACA N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide Methyl(2S)-2-{[1-(5-fluoropentyl)-1H-5F-ADB (5F-MDMB-PINACA) indazole-3-carbonyl]amino}-3,3-dimethylbutanoate AB-PINACA N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl)-1H-indazole-3-carboxamide (1-Pentyl-1H-indol-3-yl)(2,2,3,3-UR-144 tetramethylcyclopropyl)methanone Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-5F-PB-22 carboxylate 4-Fluoroamphetamine (4-FA) 1-(4-Fluorophenyl)propan-2-amine ADB-CHMINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide CUMYL-4CN-BINACA 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide ADB-FUBINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide Methyl (2S)-2-{[1-[(4-FUB-AMB (MMB- or AMB-FUBINACA) fluorophenyl)methyl]indazole-3-carbonyl]amino}-3-methylbutanoate 1-(2H-1,3-benzodioxol-5-yl)-2-N-ethylnorpentylone (ethylamino)pentan-1-one) DOC 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine HHC, hexahydrocannabinol 6,6,9-Trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol HHC-O acetate, HHCO, HHCOA, (6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrocannabinol O-Acetate hexahydrobenzo[c]chromen-1-yl) trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-yl acetate HHC-P,hexahydrocannabiphorol 3-Heptyl-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol; 3-heptyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol tetrahydrocannabidiol, Hydrogenated 2-(2-Isopropyl-5-methylcyclohexyl)-5-cyclohexyl CBD pentylbenzene-1,3-diol tetrahydrocannabiphorol, Delta-9- 3-Heptyl-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol;  3-Heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol hexahydrocannabihexol,HHC-H 3-Hexyl-6,6,9-trimethyl-6a,7,8,9,10,10a- hexahydrobenzo[c]chromen-1-ol; 3-hexyl-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol delta-8- 3-heptyl-6aR,7,10,10aR-tetrahydro-6,6,9-Tetrahydrocannabiphorol, JWH 091, THC- trimethyl-6H-dibenzo[b,d]pyran-1-ol; 3-heptyl-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol  Tetrahydrocannabutol, Delta-9-THCB, 3-butyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-Delta-9-THC-C4,  6H-dibenzo[b,d]pyran-1-ol;  Delta-9-THC-butyl 3-butyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol 6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-9-Hydroxyhexahydrocannabinol, hexahydro-6H-benzo[c]chromene-1,9-diol; 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1,9-diol acetate, 6aR,7,10,10aR-tetrahydro-6,6,9-trimethyl-3-Δ8-Tetrahydrocannabinol  pentyl-6H-dibenzo[b,d]pyran-1-ol, 1-acetate

Δ8-THC-O-Acetate methylether, 6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-1-methyl-Δ8-THC, trimethyl-3-pentyl-6H-dibenzo[b,d]pyran Δ8-Tetrahydrocannabinol methylether acetate, 3-heptyl-6aR,7,8,10aR-tetrahydro-6,6,9-Δ9-Tetrahydrocannabiphorol Acetate, delta-9- trimethyl-6H-dibenzo[b,d]pyran-1-ol, 1-acetate

 (6aR,10aR)-3-hexyl-6a,7,8,10a-tetrahydro-delta-9-Tetrahydrocannabihexol, delta-9-THC- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol

HHC-P-O-acetate, (6aR,10aR)-6,6,9-trimethyl-3-heptyl-hexahydrocannabiphorol acetate 6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-yl acetate  (6aR,10aR)-3-hexyl-6a,7,10,10a-terahydro-delta-8-tetrahydrocannabihexol delta-8-THC- 6,6,9-trimethyl-6H- dibenzo[b,d]pyran-1-ol

CC9 3-nonyl-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol derivatives, salts, or esters of the above.  SECOND SCHEDULE Amended by:  L.N. 26 of 1987.  Substituted by:  L.N. 70 of 1988.  Amended by:  L.N. 103 of 1989;  L.N. 78 of 1998;  L.N. 183 of 1999.  L.N. 173 of 2010;  L.N. 413 of 2012;  L.N. 112 of 2021;  L.N. 294 of 2021;  L.N. 295 of 2021;  L.N. 164 of 2022;  L.N. 251 of 2022;  L.N. 157 of 2023;  L.N. 180 of 2024;  L.N. 99 of 2025; L.N. 47 of 2026. (Regulation 2)

International or other nonproprietary name Chemical name or other trivial name ALLOBARBITAL 5, 5-diallylbarbituric acid AMFEPRAMONE, DIETHYLPROPION 2-(diethylamino) propiophenone AMINOREX 2-amino-5-phenyl-2-oxazoline AMOBARBITAL 5-ethyl-5-(3-methylbutyl) barbituric AMPHETAMINE (±)-2-amino-l-phenylpropane BARBITAL 5, 5-diethylbarbituric acid BENZPHETAMINE N-benzyl-N, -dimethylphenethylamine BROTIZOLAM 2-bromo-4(o-chlorophenyl)-9-methyl-6H-thieno [3,2-f]-s-triazolo [4,3-a] BUPRENORHINE 21-cyclopropyl-7-alpha-[(S)-l-hydroxy-1,2,2-trimethylpropyl]-6,14-endoethano-6,7,8,14-tetrahydrooripavine BUTALBITAL 5-allyl-5-isobutylbarbituric acid BUTOBARBITAL 5-butyl-5-ethylbarbituric acid CATHINE d-threo-2-amino-1-hydroxy-l-phenylpropane CHLORAL HYDRATE 2, 2, 2-trichloroethane-1, 1-diol CHLORDIAZEPOXIDE 7-chloro-2-(methylamino)-5-phenyl-3H-1, 4benzodiazepine-4-oxide CHLORPHENTERMINE p-chloro--dimethylphenethlylamine CYCLOBARBITAL 5-(l-cyclohexen-l-y1)-5-ethylbarbituric CUMYL-PEGACLONE 5-pentyl-2-(-phenylpropan-2-yl)-2,5-dihydro-1H-3-methoxyphencyclidine (also known as 3- pyrido[4,3-b]indol-1-one MeO-PCP) 1-(1-(3- methoxyphenyl)cyclohexyl)piperidine DIPHENIDINE 1-(1,2-diphenylethyl)piperidine CLONAZOLAM (also known as clonitrazolam) 6-(2-chlorophenyl)-1-methyl-8-nitro-4Hbenzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) DICLAZEPAM (also known as Ro 5-3448) 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin2-one FLUBROMAZOLAM 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]-DEXAMPHETAMINE (+)-2-amino-1-phenylpropane and other compounds 7-chloro-1, 3-dihydro-1-methyl-5-phenyl-2H-the chemical structure of 1, 4-benzodiazepine-2-one DIHYDRO-1:4 BENZODIAZEPINE or DIHYDRO-1:5 BENZODIAZEPINE to any degree OL delta-9-tetrahydro- (6aR, 10aR)-6a7, 8, 10a-tetrahydro-6,6,9-nol and its stereochemical trimethyl-3-penatyl-6H-dibenzo [b,d] pyran-1-(This item refers to only one of o1 stereochemical variants of delta-9-tetrahydrocannabinol, namely(-)-trans-delta-9-tetrahydrocannabinol.) ETHCHLORVYNOL ethyl-2-chlorovinylethynylcarbinol l-ethynylcyclohexanolcarbamate FENCAMFAMIN dl-N-ethyl-3-phenylbicyclo (2,2,1)-heptan-2amine dl-3,7-dihydro-1, 3 dimethyl-7-(2-[(l-methyl2-phenylethyl) amino] ethyl)-1H-purine-2, 6-dione FENFLURAMINE N-ethyl--methyl-m(trifluoromethyl) phenethylamine FENPROPOREX dl-3-[(a-methylphenethyl)amino] propionitrile GLUTETHIMIDE 2-ethyl-2-phenylglutarimide (±)-2-(2-Chlorophenyl)-2-methylaminocyclohezanone LEVAMPHETAMINE 1-a-methylphenethylamine LEVOMETHAMPHETAMINE l-N, a-dimethylphenethylamine 5-(p-chlorophenyl)-2, 5-dihydro-3H-imidazo [2, 1-a] isoindol-5-ol MECLOQUALONE 3-(o-chlorophenyl)-2-methyl-4 (3H)-quinazolinone dl-N-(3-chloropropyl)-a-methylphenethylamine MEPHENTERMINE N--trimethylphenethylamine MEPROBAMATE 2-methyl-2-propyl-1, 3-propanediol dicarbamate 3-(-methylphenethyl)-N-phenylcarbamoyl) sydnone imine METHAMPHETAMINE (+)-2-methylamino-l-phenylpropane HETAMINE RACEMATE 2-methyl-3-o-tolyl-4(3H)-quinazolinone METHAQUALONE METHYLPHENIDATE 2-phenyl-2 (2-piperidyl) acetic acid, methyl ester METHYLPHENOBARBITAL 5-ethyl-l-methyl-5-phenylbarbituric acid METHYPRYLON 3, 3-diethyl-5-methyl-2, 4-piperidine-dione MDMB-4-en-PINACA methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl] amino}butanoate 4F-MDMB-BICA methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl] amino}-3,3-dimethylbutanoate N-ETHYLAMPHETAMINE dl-N-ethyl-a-methylphenylethylamine PARALDEHYDE acetaldehyde trimer 2-amino-5-phenyl-2-oxazolin-4-one 2-or imino-5-phenyl-4-oxazolidinone PENTAZOCINE 1, 2, 3, 4, 5, 6, hexahydro-6, (3-methyl-2-butenyl)-2, 3benzazocin-8-o1 PENTOBARBITAL 5-ethyl-5-(1-methylbutyl) barbituric PHENCYCLIDINE 1-(l-phenylcyclohexyl) piperidine PHENDIMETRAZINE (+)-3, 4-dimethyl-2-phenylmorpholine PHENMETRAZINE 3-methyl-2-phenylmorpholine PHENOBARBITAL 5-ethyl-5-phenylbarbituric acid PHENTERMINE a,a-dimethylphenethylamine PIPRADROL 1,l-diphenyl-l-(2-piperidyl) methanol PROPYLHEXEDRINE dl-1-cyclohexyl-2-methylaminopropane PYROVALERONE dl-l-(4-methylphenyl)-2-(l-pyrrolidinyl)-lpentanone SECBUTABARBITAL 5-sec-butyl-5-ethylbarbituric acid SECOBARBITAL 5-allyl-5-(l-methylbutyl) barbituric SPA, LEFETAMINE (-)-l-dimethylarnine-1, 2, diphenylethane TIANEPTINE 7-[(3-Chloro-6,11-dihydro methyldibenzo[c, thi f][1,2] amino] heptanoic acid VINYLBITAL 5-(l-methyl-butyl)-5-vinylbarbituric ZIPEPROL -(-µ ethoxybenzl)-4-((ß-methoxphenethyl)-1-piperazineethanol CHLORMETHIAZOLE 5-(2-chloroethyl)-4-methyl-1,3-thiazole AMINEPTINE (7-[(10, 11-dihydro-5Hd cyclohepten-5-y-5-yl) amino]heptanoic TRAMADOL (±)-trans-2-Dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol ZOLPIDEM (N,N,6-trimethyl-2-ptolylimidazo[ α]pyridine-3-acetamide) 2C-B (4-bromo-2,5-dimethoxyphenethylamine) GHB (γ-hydroxybutyric acid) AB-CHMINACA N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1 H carboxamide 5F-ADB (5F-MDMB-PINACA) Methyl(2S)-2-{[1-(5-fluoropentyl)-1 indazole-3-carbonyl]amino}-3,3-dimethylbutanoate AB-PINACA N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl)-1H-indazole-3-carboxamide (1-Pentyl-1 -indol-3-yl)(2,2,3,3-UR-144 H tetramethylcyclopropyl)methanone 5F-PB-22 Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 1-(4-Fluorophenyl)propan-2-amine. 4-Fluoroamphetamine (4-FA) AB-FUBINACA (or FUB-AMB) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 5F-AMB-PINACA (or 5F-AMB or 5F-MMB- methyl 2-({[1-(5-fluoropentyl)-1H-indazole-3-yl]carbonyl}amino)-3-methylbutanoate PINACA) 5F-MDMB-PICA (or 5F-MDMB-2201) methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate 4F-MDMB-BINACA (or 4F-MDMB-BUTIN- methyl 2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate

4-bromomethcathinone 1-(4-Bromophenyl)-2-(methylamino)propan-1-one 4-chloromethcathinone or clephed- 1-(4-chlorophenyl)-2-(methylamino)propan-1-one

(or NEH, Hexen, Ethyl-Hex, 2-(ethylamino)-1-phenylhexan-1-one N-ethylhexedrone

2-(Ethylamino)-1-N-Ethylnorpentedrone, phenylpentan-1-one PV-7, α-PHP, α-pyrrolidinohex- 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one

(or Ro 11-5073/000) 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine Y-7131 or Depas) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine". 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one 2-methylmethcathinone, 2-(Methylamino)-1-(2-methylphenyl)propan-1-one 3-methylmethcathinone, 3-MMC 2-(methylamino)-1-(3-methylphenyl)propan-1-one

3-chloromethcathinone, 3-CMC 1-(3-chlorophenyl)-2-(methylamino)propan-1-one".

ADB-BUTINACA N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-butyl-1H-indazole-3-carboxamide)

α-PiHP 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one)

BROMAZOLAM 8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one

2-FLUORODESCHLOROKETAMINE (2- 2-(2-fluorophenyl)-2-methylamino-

cyclohexanone

CARISOPRODOL (2RS)-2-[(carbamoyloxy)methyl]-2-methylpentyl (1-methylethyl)carbamate salts or esters of the above. THIRD SCHEDULE

(Regulations 3 and 4) FOURTH SCHEDULE  Amended by:  L.N. 426 of 2012; (Regulation 13(4))  L.N. 380 of 2017; L.N. 100 of 2025. CONFIDENTIAL

terms of regulation 13 - Prescriptions for flunitrazepam, mecloqualone, and phenmetrazine and secobarbital or a combination of secobarbital amobarbital in tablet or capsule form or in sachet or cachet and their respective salts or esters) IMPORTANT - Prescription for these preparations can only be issued after written obtained from the Superintendent of Public Health for each prescription. ADDRESS OF PATIENT ............................................... ............................................... VALID IDENTIFICATION ............................................... NUMBER ............................................... PREPARATION AND ............................................... ............................................... PRESCRIBED ............................................... ............................................... PRESCRIPTION ............................................... REF. NO. OF APPROVAL SUPERINTENDENT OF HEALTH ............................................... OF MEDICAL PRACTITIONER ............................................... Letters) ............................................... ............................................... ............................................... ...............................................  FIFTH SCHEDULE Amended by:  L.N. 426 of 2012;  (Regulation 13(5)) L.N. 380 of 2017; L.N. 100 of 2025.

CONFIDENTIAL (Return in terms of regulation 13 - Prescriptions for mecloqualone, methaqualone, and phenmetrazine and secobarbital or a combination of secobarbital amobarbital in tablet or capsule form or in sachet or cachet and their respective or esters)

NAME AND ADDRESS OF PATIENT ............................................. ............................................. LEGALLY VALID IDENTIFICATION ............................................. DOCUMENT NUMBER NAME OF PREPARATION AND STRENGTH ............................................. ............................................. QUANTITY PRESCRIBED ............................................. DATE OF PRESCRIPTION ............................................. NAME OF PRESCRIBER ............................................. SIGNATURE OF APOTHECARY ............................................. NAME (Block Letters) ............................................. DH LICENCE NUMBER ............................................. ADDRESS (of Pharmacy) ............................................. ............................................. ............................................. DATE OF DISPENSING ............................................. SIXTH SCHEDULE  Amended by: L.N. 426 of 2012. (Regulation 13)

address of patient .................................................................................

Identification Document Number ........................................................ prescription .............................................................................................. drug ........................................................................................................

prescribed ............................................................................................... medical practitioner, dental surgeon or dentist who has prescribed the ......................................................................................................................... SEVENTH SCHEDULE

(Regulation 7)

PRESCRIPTION FOR NARCOTIC AND PSYCHOTROPIC DRUGS (Only one item may be prescribed on this Form)

A. TO BE FILLED BY PRESCRIBER C. TO BE FILLED BY  DISPENSING APOTHECARY PATIENT Name and Surname ................................................................. PATIENT Address ................................................................................... Surname ITEM Quantity (incl. Form& Dose) I.D Directions for use Additional information in respect of Prescriptions for METHADONE Male Female

ITEM Expected Duration of Treatment .................... Quanity Supplied Medical Indication ........................................ Total Quantity in Units ............................................................... PRESCRIBER Med Council Reg. No. Total Quantity in Weight/Measure ............................................... Name and Surname .......................................................... PRESCRIPTION ORIGIN Address .......................................................................... Hospitals .............................................................

Signature ............................................... Date .................... Govt. Clinics ....................................................... .. Private ....................................................... .. B. FOR OFFICIAL USE ONLY DISPENSER To be filled by Government Dispenser Signature................................................................ . PRESCRIPTION TYPE Pharmacy Board Reg. No Pink Form Schedule III Others Dispensary Address Direct Postal .........................................................................

LOCATION DISPENSER Dispensary

To be filled by Coder DH Licence No.

Item No. Prescription Origin Date

Serial No. EIGHTH SCHEDULE

(Regulation 7)

REQUEST FOR PRESCRIPTION FORMS FOR NARCOTIC AND PSYCHOTROPIC DRUGS

........................ booklet/s by ..................... prescription forms. surname of prescriber ........................................................................... ( IN BLOCK LETTERS) address .....................................................................................................

LETTERS) ....................................... Med. Council Reg. No.

FOR OFFICIAL USE

..................... booklet/s by ..................... prescription forms. ........................ to ........................

withdrawn personally by prescriber.

........................................... ........................................ Prescriber Date forwarded by mail. Forwarded by .................................... on ...........................

be attached.  NINTH SCHEDULE Added by:  L.N. 65 of 1986.  (Regulation 9) Amended by:  L.N. 34 of 1989; DEPARTMENT OF HEALTH L.N. 426 of 2012.

CONTROL CARD FOR NARCOTIC/PSYCHOTROPIC DRUGS Name and Surname of Patient .................................... Address ................................................ A legally valid Identification Document Number (where available, or Passport No., in case of Non-Maltese citizens who do not hold a legally valid identification document): ................................................

Date of Issue of Card .......... Valid till ........................ ............................................................. Superintendent of

(Columns 1 - 4 to be filled by Prescriber) (Columns 5 - 8 to be filled by Dispensing

Date of Name of Amount Signature of Amount Date of Signature Prescription Drug. Prescribed Medical Dispensed Dispensing Apothecary Form and Practitioner Dose and Medical Council Reg. No. TENTH SCHEDULE  Added by: L.N. 65 of 1986. (Regulation 9)

REQUEST FOR THE ISSUE/RENEWAL OF A CONTROL CARD FOR NARCOTIC AND PSYCHOTROPIC DRUGS

Superintendent of Public Health request that Mr/Ms............................................................. aged .............

........................................................ residing at .................................... ..............................................................................................................................

issued with a control card for narcotic/psychotropic drugs (§) the control card for narcotic/psychotropic drugs renewed.(§)

whatever is inapplicable.

Medical Practitioner .......................................................................... Address of  Practitioner ..................................................................................... .....................................................................................

..................................................................................... ..................................................................................... Council Reg. No. .....................................................................................

.......................................

non-Maltese citizens not holding an I.D. Card, the Passport No., is to be inserted; in the minor the particulars inserted are to be in relation to the I. D. Card or passport of the father, guardian.